FDA — authorised 25 May 2023
- Marketing authorisation holder: BLUE EARTH
- Status: approved
FDA authorised Posluma on 25 May 2023
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. FDA authorised it on 25 May 2023.
BLUE EARTH holds the US marketing authorisation.